#China #Hangzhou #Innovent Biologics #ADCs #Altruist Biologics

Altruist Biologics Achieves Major Breakthrough in ADC Production

In a notable advance for the biopharmaceutical industry, Altruist Biologics, a subsidiary of Innovent Biologics, has received key regulatory approvals for segmented production of antibody-drug conjugates (ADCs) at its facility in Hangzhou, China. This achievement marks the first time that a facility in the region has successfully undergone a tri-provincial regulation process, a testament to the company’s rigorous quality and operational standards.

A Unified Quality System in Action

This regulatory milestone reflects Altruist Biologics’ commitment to quality and safety. The facility is designed with an integrated quality management system that meets stringent compliance requirements. According to Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, “Quality is at the core of our operations. With our advanced global quality system, we ensure that we meet the highest standards, allowing us to continually support the evolving needs of our partners around the world.”

The company’s dedication to maintaining exceptional quality is crucial as it supports the broader mission of advancing cutting-edge therapies that can change patient lives.

Advanced Manufacturing Capabilities

Altruist Biologics’ Hangzhou facility features a standalone ADC bioconjugation unit, fully equipped to manufacture a variety of high-potency ADCs, tailored for both clinical and commercial applications. The facility is built to accommodate both small- and large-scale production, facilitating a smooth workflow from development through to manufacturing. This includes state-of-the-art laboratories for continuous innovation and quality control.

The current production capabilities include single-use reactor systems with a conjugation scale of up to 500 liters, and additional facilities under development that will accommodate larger scales ranging from 1,000 liters to 5,000 liters. This expansion is crucial for meeting increasing demands for scalable drug substance manufacturing.

Additionally, the facility incorporates cutting-edge technology such as fully automated, isolator-based aseptic filling systems, equipped with several lyophilizers—ensuring low contamination risk during production processes. Safety measures are paramount, especially considering the handling of high-potency active pharmaceutical ingredients (HPAPIs), with the facility designed to adhere to an Occupational Exposure Limit (OEL) of 5 ng/m³.

Proven Track Record

Altruist Biologics has already successfully managed more than 40 projects encompassing ADC and AXC products, showcasing their experience from pre-IND phases through to phase-three clinical trials and process performance qualifications. Their impressive portfolio demonstrates a high success rate, having achieved a greater than 99.8% success rate over 2,000 commercial batch productions.

With over ten years in bioprocessing, Altruist has been instrumental in commercializing 18 drugs and maintaining a robust global regulatory presence, with over 100 filings worldwide across regulatory bodies such as the FDA, EMA, and more.

Conclusion: Committed to Innovation and Patient Care

As Altruist Biologics continues to expand its capabilities in biomanufacturing, the company remains steadfast in its commitment to developing accessible and high-quality biopharmaceuticals. The recent approval not only enhances its operational flexibilities but also signifies its ongoing dedication to creating innovative therapies that address patient needs globally. For more information on Altruist Biologics and their range of capabilities, you can visit their official website at www.altruistbio.com.